Sponsors

Study researchers are actively recruiting participants for a global, 12-month Phase 3 study testing lenabasum for dermatomyositis. If you are interested in participating or learning more, visit: https://www.corbuspharma.com/clinical-trials/phase-3-study-in-dermatomyositis. The study is organized by Corbus Pharmaceuticals, a company focused on the development and commercialization of novel therapeutics for inflammatory and fibrotic diseases by harnessing its platform of endocannabinoid system-targeting drug candidates. The company’s lead product candidate, lenabasum, is an oral, selective cannabinoid receptor type 2 agonist designed to reverse chronic inflammation and halt fibrotic processes.

Orphazyme is a late-stage biopharmaceutical company focused on developing novel treatment options for patients with rare, orphan diseases. Our work is focused on the cell-protective properties of the heat-shock response, a natural defense mechanism in all our cells. Orphazyme’s lead compound, arimoclomol, is being developed as a potential treatment for several protein-misfolding diseases, including sporadic inclusion body myositis (sIBM). A phase 2/3 clinical trial investigating the use of arimoclomol for sIBM is ongoing with results expected in the first half of 2021.

CSI Pharmacy is a nationwide specialty pharmacy, founded by pharmacists, dedicated to servicing patients with chronic and rare illnesses requiring complex care. We are invested in improving the health—and the lives—of the people we serve by offering expert clinicians, passionate advocates, committed healthcare partners and strategic reimbursement experts. Our goal is to optimize patient outcomes, while treating patients as if they were members of our family. Twenty percent of the patients we treat have a form of myositis. We are proud to be a sponsor of Myositis Awareness Month!

Diplomat Speciality Infusion Group is a nationwide specialty pharmacy.